Private equity firm Nautic Partners has acquired Omnicare Clinical Research from Omnicare Inc. Based in King of Prussia, Penn., Omnicare Clinical Research provides early phase, phase II/III and late phase clinical trials for the pharmaceutical, biotechnology and medical device industries. Terms of the deal were not released. Nautic Partners is a middle-market private equity firm with over $2.5 billion under management.
Nautic Partners LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has acquired Omnicare Clinical Research (“Omnicare CR”) from Omnicare, Inc. Headquartered in King of Prussia, PA. Through its specialized business unit model, Omnicare CR conducts early phase, phase II/III and late phase clinical trials for the pharmaceutical, biotechnology and medical device industries. The Company also provides technical services that support clinical trials, with a particular focus on data management and biostatistics services.
Omnicare CR is a global CRO with approximately 900 employees and offices in 32 countries. Over the last five years, Omnicare CR has completed over 1,500 studies involving nearly 22,000 investigators and over 337,000 patients. Therapeutic areas of focus include oncology, cardiovascular, diabetes, CNS, vaccines and infectious diseases. As part of the transaction, Omnicare, Inc. has provided Omnicare CR exclusive access to its proprietary database of de-identified information. This license is exclusive in the field of clinical research and lasts for five years.
“The CRO industry is an attractive growth segment of the healthcare industry and we are pleased to be working with the Omnicare CR management team,” said Chris Crosby, Managing Director of Nautic. “Omnicare CR has carved out an attractive niche in the CRO industry as a global, full-service provider serving the mid-sized pharmaceutical market, the medical device market and the biotechnology market.”
“We are excited to be partnering with Nautic as the Company continues to build a successful and leading global CRO business,” said James Pusey, President and Chief Executive Officer of Omnicare CR. “Our new partner has extensive experience investing in the healthcare industry and will bring significant financial and strategic support. Additionally, our debt-free balance sheet positions us well for sustained growth and long term stability.”
Omnicare CR is Nautic Partners’ tenth investment from its most recent fund, Nautic Partners VI, LP. It is the third healthcare investment in this fund. Other representative Nautic healthcare investments include Reliant Hospital Partners, LLC, American Imaging Management, Inc., AXIA Health Management, Inc., Healthcare Payment Specialists, LLC and Medegen, Inc.
About Nautic Partners
Founded in 1986, Nautic Partners is a middle-market private equity firm with over $2.5 billion of equity capital under management. The firm has completed over 110 transactions in partnership with management and delivered successful results to investors over three decades. Nautic targets equity investments of $25-$75 million, representing majority ownership in niche businesses with strong market share and growth potential, identified value enhancement opportunities and strong management teams. Areas of focus include business services, manufacturing, healthcare and communications. For more information, please visit www.nautic.com.
About Omnicare Clinical Research
Omnicare Clinical Research is a leading global, full-service contract research organization headquartered in King of Prussia, Pennsylvania. With locations in 32 countries, the firm has relationships with the world’s leading pharmaceutical, biotech and medical device companies. Omnicare CR specializes in specific, client-focused business units — early phase, phase II/III, late phase, medical device, technical services and pharmaceutics. For more information on Omnicare CR, visit: http://www.omnicarecr.com.